As defined by the National Cancer Institute (NCI), the mission of UCLA´s Jonsson Comprehensive Cancer Center is as follows:
NCI-designated Cancer Centers are a major source of discovery of the nature of cancer and of the development of more effective approaches to cancer prevention, diagnosis and therapy. They also deliver medical advances to patients and their families, educate health-care professionals and the public and reach out to underserved populations. They are characterized by: strong organizational capabilities; institutional commitment; trans-disciplinary, cancer-focused science; experienced scientific and administrative leadership and state-of-the-art cancer research and patient care facilities.
In the late 1960s, a group of scientists and volunteers at UCLA came together to develop a cancer center they hoped would become renowned for excellence in research, education and patient care.
In 1976, the cancer center at UCLA was designated "comprehensive" by the National Cancer Institute (NCI). Of the 67 NCI cancer center programs nationwide, only 41 receive the gold-star comprehensive status. UCLA's Jonsson Comprehensive Cancer Center (JCCC) receives this honor for maintaining the highest standards of excellence in patient care, education, basic science, clinical research and cancer prevention.
JCCC has established an international reputation in a number of areas, such as:
- Developing new cancer therapies
- Providing the best in experimental and traditional treatments
- Expertly guiding and training the next generation of medical researchers
Numerous successful targeted therapies were developed based on basic science done in UCLA laboratories and later clinical research with UCLA patients. A few of the more well-known therapies include:
- Herceptin, a targeted breast cancer drug and the first approved treatment that attacks cancer at its genetic roots
- Gleevec, a once-a-day pill that targets a common form of adult leukemia called chronic myelogenous leukemia, or CML
- Sprycel, also a pill that targets CML
- Tarceva, a targeted lung cancer drug
- Avastin, a targeted drug for colorectal cancer and lung cancer
These treatments are just the most well-known of our JCCC firsts.
With a membership of more than 450 physicians and scientists, JCCC is one of the largest comprehensive cancer centers in the nation. We handle more than 156,000 patient visits per year and conduct hundreds of clinical trials, providing the latest in experimental cancer treatments. Our depth lets us offer a wide array of benefits to patients.
For more information, please contact us at email@example.com.